RIASTAP

This brand name is authorized in United States. It is also authorized in Canada, Cyprus, Finland, France, Ireland, Malta, New Zealand, Poland, Spain, UK.

Active ingredients

The drug RIASTAP contains one active pharmaceutical ingredient (API):

1	Human fibrinogen UNII N94833051K - FIBRINOGEN HUMAN
	Human fibrinogen (coagulation factor I), in the presence of thrombin, activated coagulation factor XIII (F XIIIa) and calcium ions is converted into a stable and elastic three-dimensional fibrin haemostatic clot. The administration of human fibrinogen concentrate provides an increase in plasma fibrinogen level and can temporarily correct the coagulation defect of patients with fibrinogen deficiency.
	Read more about Human fibrinogen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RIASTAP Powder for solution for injection or infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BB01	Human fibrinogen	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BB Fibrinogen
Discover more medicines within B02BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02393352
ES	Centro de información online de medicamentos de la AEMPS	72725
FI	Lääkealan turvallisuus- ja kehittämiskeskus	422474
FR	Base de données publique des médicaments	61179660
GB	Medicines & Healthcare Products Regulatory Agency	185608
MT	Medicines Authority	MA665/00401
NZ	Medicines and Medical Devices Safety Authority	18613
PL	Rejestru Produktów Leczniczych	100244762
US	FDA, National Drug Code	63833-891